Mega Genomics Limited (6667.HK)

9,700 -0,090 (-0,92%) In data: 11:31AM HKT. Mercato aperto.

Mega Genomics Limited

401 Health Work
North Garden Road Haidian District
Beijing
China
400-008-0280
https://www.megagenomics.cn

Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno: 229

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Lin Lin	Executive Chairman	1,72M	N/D	1975
Ms. Jing Jiang	CFO & Executive Director	655,01k	N/D	1981
Dr. Rong Yu	Executive Director & Honorary Co-Chairperson	N/D	N/D	1971
Yong Zhai	Co-owner	N/D	N/D	N/D
Mr. Cong Li	Head of Information Technology	N/D	N/D	1984
Ms. Wai Kam Ng A.C.I.S., A.C.S.	Company Secretary	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in HKD.

Descrizione

Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services, including brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer's disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson's disease risk assessment; full-scale cancer risk assessment packages; and cardiovascular and cerebrovascular disease risk assessment packages. The company also provides advanced testing services, such as hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; and telomere length genetic testing that assesses the cell age and aging rate of a person. In addition, it offers executive testing services, such as personal whole genome test plus, a service that assesses the risk of developing multiple types of diseases and provides interpretation for various individual traits and medication advice; and whole exome sequencing package for adults, a service that assesses the risk of developing multiple high-risk diseases, hereditary cancers, recessive genetic diseases, and types of complex diseases, as well as multiple drugs, dietary nutrition items, and exercise and fitness items. Further, it develops folate metabolic capacity assessment testing kits to assess the risk of developing cardiovascular and cerebrovascular diseases; ApoE gene testing kits used to assess the risk of developing Alzheimer's disease; BRCA1/ BRCA2 gene mutation testing kits; Alzheimer's disease screening kits; colorectal cancer screening kits; gastric cancer screening kits; lung nodule auxiliary diagnostic kits; and cervical cancer screening kits. The company serves health checkup centers and hospitals. Mega Genomics Limited was founded in 2016 and is headquartered in Beijing, China.

Governance aziendale

L'ISS Governance QualityScore di Mega Genomics Limited al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.